^
    Back
    Association details:
    Biomarker:BRAF D594G
    Cancer:Melanoma
    Drug:ulixertinib (BVD-523) (ERK2 inhibitor, ERK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2022
    Title:

    Updated clinical outcomes from ULI-EAP-100, an intermediate expanded access program for ulixertinib (BVD-523).

    Published date:
    05/26/2022
    Excerpt:
    ULI-EAP-100 (NCT04566393) is an ongoing intermediate expanded access protocol (EAP) that offers ulixertinib to US patients with advanced solid tumors harboring MAPK pathway alterations..A BRAF D594G melanoma pt’s tumor rapidly shrunk with monotherapy permitting surgery and rendering pt with no evidence of disease...
    DOI:
    10.1200/JCO.2022.40.16_suppl.e15101
    Trial ID:
    NCT04566393